Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 2
1978 1
1979 2
1980 4
1981 1
1982 3
1984 1
1985 3
1986 1
1987 8
1988 3
1989 5
1990 6
1991 7
1992 9
1993 7
1994 3
1995 7
1996 5
1997 8
1998 5
1999 6
2000 2
2001 9
2002 10
2003 5
2004 6
2005 10
2006 10
2007 9
2008 5
2009 9
2010 8
2011 9
2012 7
2013 5
2014 11
2015 13
2016 12
2017 11
2018 8
2019 3
2020 8
2021 7
2022 1
2023 5
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

265 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Stage III Chronic Lymphocytic Leukemia"
Page 1
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. Hallek M, et al. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14. Blood. 2018. PMID: 29540348 Free article.
The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the d …
The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), …
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Byrd JC, Woyach JA, Furman RR, Martin P, O'Brien S, Brown JR, Stephens DM, Barrientos JC, Devereux S, Hillmen P, Pagel JM, Hamdy A, Izumi R, Patel P, Wang MH, Jain N, Wierda WG. Byrd JC, et al. Blood. 2021 Jun 17;137(24):3327-3338. doi: 10.1182/blood.2020009617. Blood. 2021. PMID: 33786588 Free PMC article. Clinical Trial.
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase 1/2 trial (ACE-CL-001). ...Pat …
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy …
Genomic aberrations and survival in chronic lymphocytic leukemia.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Döhner H, et al. N Engl J Med. 2000 Dec 28;343(26):1910-6. doi: 10.1056/NEJM200012283432602. N Engl J Med. 2000. PMID: 11136261 Free article.
BACKGROUND: Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leukemia. We used this method to identify chromosomal abnormalities in patients with chronic lymphocytic leukemia and …
BACKGROUND: Fluorescence in situ hybridization has improved the detection of genomic aberrations in chronic lymphocytic leu …
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K. Al-Sawaf O, et al. Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5. Lancet Oncol. 2020. PMID: 32888452 Clinical Trial.
BACKGROUND: Venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia. We compared the long-term efficacy after treatment cessation of the combination of venetoclax plus obinutuzuma …
BACKGROUND: Venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymp …
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter M, Niemann CU, da Cunha-Bang C, Kater A, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M. Langerbeins P, et al. Blood. 2024 Jun 20;143(25):2588-2598. doi: 10.1182/blood.2023022564. Blood. 2024. PMID: 38620092
We evaluated the chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) in patients with CLL treated first line with targeted drugs (n = 991) or chemoimmunotherapy (n = 1256). ...In a matched-pair analysis, PFS differences in targeted th …
We evaluated the chronic lymphocytic leukemia International Prognostic Index (CLL-IPI) in patients with CLL trea …
Chronic lymphocytic leukemia.
Kay NE, Hamblin TJ, Jelinek DF, Dewald GW, Byrd JC, Farag S, Lucas M, Lin T. Kay NE, et al. Hematology Am Soc Hematol Educ Program. 2002:193-213. doi: 10.1182/asheducation-2002.1.193. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446424 Review.
This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current information on the diagnosis, biology, and intervention required to more fully develop algorithms for management of this disease. Emphasis on early …
This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current informatio …
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M; international group of investigators; German CLL Study Group (GCLLSG). Eichhorst B, et al. Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20. Lancet Oncol. 2016. PMID: 27216274 Clinical Trial.
METHODS: Treatment-naive fit patients with chronic lymphocytic leukaemia (aged 33-81 years) without del(17p) were enrolled after undergoing a central screening process. ...INTERPRETATION: The combination of fludarabine, cyclophosphamide, and rituximab remains …
METHODS: Treatment-naive fit patients with chronic lymphocytic leukaemia (aged 33-81 years) without del(17p) were enrol …
Genotypic prognostic markers.
Stilgenbauer S, Döhner H. Stilgenbauer S, et al. Curr Top Microbiol Immunol. 2005;294:147-64. doi: 10.1007/3-540-29933-5_9. Curr Top Microbiol Immunol. 2005. PMID: 16323431 Review.
In chronic lymphocytic leukemia (CLL), genetic analyses by fluorescence in situ hybridization (FISH) and DNA sequencing have greatly improved our understanding of pathogenic events and prognostic markers. ...V-gene usage, VDJ structure, and gene expres …
In chronic lymphocytic leukemia (CLL), genetic analyses by fluorescence in situ hybridization (FISH) and DNA sequencing …
Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation.
Playa-Albinyana H, Arenas F, Royo R, Giró A, López-Oreja I, Aymerich M, López-Guerra M, Frigola G, Beà S, Delgado J, Garcia-Roves PM, Campo E, Nadeu F, Colomer D. Playa-Albinyana H, et al. Leukemia. 2024 Mar;38(3):557-569. doi: 10.1038/s41375-023-02095-5. Epub 2023 Nov 28. Leukemia. 2024. PMID: 38017105 Free PMC article.
Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical behavior. In 5-10% of patients the disease transforms into a diffuse large-B cell lymphoma known as Richter transformation (RT), which is associa …
Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical behavior. In 5-10% …
Prognostic markers and standard management of chronic lymphocytic leukemia.
Stilgenbauer S. Stilgenbauer S. Hematology Am Soc Hematol Educ Program. 2015;2015:368-77. doi: 10.1182/asheducation-2015.1.368. Hematology Am Soc Hematol Educ Program. 2015. PMID: 26637745 Review.
Chronic lymphocytic leukemia (CLL) is usually diagnosed in early stage, asymptomatic patients, and, although a wealth of prognostic parameters have been identified, the standard approach is a "watch and wait" strategy irrespective of risk factor …
Chronic lymphocytic leukemia (CLL) is usually diagnosed in early stage, asymptomatic patients, and, although a w …
265 results